Skip to main content

Table 3 Positive findings grouped by cancer type

From: Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study

Cancer type

Number (%)

Genes with clinically significant variants detected

Gastrointestinal

271 (33.6)

APC, AXIN2, CDH1†, MLH1, MSH2, MSH6, MUTYH, PMS2

Breast

260 (32.2)

ATM, BARD1, CHEK2, NBN, PALB2, TP53‡

Breast and ovarian

114 (14.1)

BRCA1, BRCA2

Melanoma/skin

43 (5.3)

CDKN2A, MITF, TGFBR1 (MSSE)

Ovarian

37 (4.6)

BRIP1, RAD51C, RAD51D

Endocrine

33 (4.1)

MEN1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD

Prostate

27 (3.3)

HOXB13

CNS

11 (1.4)

NF1, NF2§, TSC1, VHL

Others

6 (0.7)

BAP1, RB1, SMARCB1

Renal

5 (0.6)

FH, FLCN

  1. CNS central nervous system
  2. Indications of higher risk from screening genes associated with hereditary cancer syndromes were most commonly related to gastrointestinal, breast, ovarian, and skin cancers. The genetic changes recorded here for each gene represent a heterozygous finding associated with an autosomal dominant condition, or a single heterozygous variant in the MUTYH gene. Certain genetic changes in the TGFBR1 gene can cause multiple self-healing squamous epithelioma (MSSE), which was classified as a hereditary cancer risk
  3. †CDH1 is also associated with breast cancer risk
  4. ‡TP53 is associated with Li-Fraumeni syndrome, which is associated with multiple cancer types
  5. §NF2 is associated with non-malignant nervous system tumors